Possibilities of predicting the HER2 / neu status in a primary tumor in breast cancer patients using <sup>99m</sup>Tc-DARPinG3
Aim. To determine informative prognostic criteria for assessing the HER2 / neu status in primary breast cancer using 99mTc-DARPinG3.Materials and methods. The study included 10 patients with breast cancer (T1-4N0-2M0) before systemic therapy, who underwent a radionuclide study using 99mTc-DARPinG3 a...
Saved in:
Main Authors: | O. D. Bragina, L. A. Tashireva, V. I. Chernov, S. M. Deyev, V. M. Tolmachev |
---|---|
Format: | Article |
Language: | English |
Published: |
Siberian State Medical University (Tomsk)
2023-01-01
|
Series: | Бюллетень сибирской медицины |
Subjects: | |
Online Access: | https://bulletin.ssmu.ru/jour/article/view/5015 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A direct comparison of the diagnostic efficacy of alternative scaffoldbased radiopharmaceuticals [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 in patients with HER2-positive breast cancer
by: O. D. Bragina, et al.
Published: (2023-10-01) -
Radionuclide imaging of HER2/neu expression in metastatic axillary lymph nodes in breast cancer patients: comparing the efficacy of [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3
by: О. D. Bragina, et al.
Published: (2025-04-01) -
Clinical possibilities of HER2-positive breast cancer diagnosis using alternative scaffold proteins
by: O. D. Bragina, et al.
Published: (2022-10-01) -
Comparative Analysis of the Clinical Use of 99mTechnetium-Labeled Recombinant Target Molecules in Different Dosages for the Radionuclide Diagnosis of Her2-Positive Breast Cancer
by: O. D. Bragina, et al.
Published: (2021-06-01) -
Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use
by: O. D. Bragina, et al.
Published: (2021-04-01)